BCL2L1 and neoplasm: Fourth, the tumor regression triggered by MEK+BCL-XL blockage we reported here using the Alb-R26Met mice is rather impressive, particularly considering the molecular and immune tumor heterogeneity recapitulated by this cancer model and by the drastically remodeling of the immune profile of treated tumors.